Epigallocatechin-3-gallate ameliorates rats colitis induced by acetic acid

Biomedicine and Pharmacotherapy

Volumn 62, Issue 3, 2008, Pages 189-196

  Ran, Zhi Hua ^a   Chen, Chi ^a   Xiao, Shu Dong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Colitis; Effect; Epigallocatechin 3 gallate; Mechanism

Indexed keywords

EPIGALLOCATECHIN GALLATE; GAMMA INTERFERON; MALONALDEHYDE; NITRIC OXIDE; PLACEBO; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; COLITIS; COLON MUCOSA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; HISTOPATHOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZATION; RAT; TREATMENT OUTCOME;

ACETIC ACID; ANIMALS; CATECHIN; COLITIS; CYTOKINES; INDICATORS AND REAGENTS; INTERFERON TYPE II; INTESTINAL MUCOSA; MALE; MALONDIALDEHYDE; NITRIC OXIDE; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 40849102807     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2008.02.002     Document Type: Article

References (34)

1. Podolsky D.K. Inflammatory bowel disease. N Engl J Med 347 (2002) 417-429
2. Reinisch W., Dejaco C., Knoflach P., Petritsch W., Vogelsang H., and Tilg H. Immunosuppressive therapy for inflammatory bowel disease: consensus by the Austrian working group on IBD. Z Gastroenterol 42 (2004) 1033-1045 discussion 1046-1047. German
3. Kumar S., Ghoshal U.C., Aggarwal R., Saraswat V.A., and Choudhuri G. Severe ulcerative colitis: prospective study of parameters determining outcome. J Gastroenterol Hepatol 19 (2004) 1247-1252
4. Ghosh S., Van Heel D., and Playford R.J. Probiotics in inflammatory bowel disease: is it all gut flora modulation?. Gut 53 (2004) 620-622
5. Meister D., and Ghosh S. Effect of fish oil enriched enteral diet on inflammatory bowel disease tissues in organ culture: differential effects on ulcerative colitis and Crohn's disease. World J Gastroenterol 11 (2005) 7466-7472
6. Stremmel W., Merle U., Zahn A., Autschbach F., Hinz U., and Ehehalt R. Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut 54 (2005) 966-971
7. Wang L.F., and Zhang H.Y. A theoretical study of the different radical-scavenging activities of catechin, quercetin, and a rationally designed planar catechin. Bioorg Chem 33 (2005) 108-115
8. Lee J.M., Karim M.M., and Lee S.H. Determination of catechin in aqueous solution by chemiluminescence method. J Fluoresc 15 (2005) 735-739
9. Cabrera C., Artacho R., and Giménez R. Beneficial effects of green tea-a review. J Am Coll Nutr 25 (2006) 79-99
10. Pierre M., and Onge S.T. Dietary fats, teas, dairy, and nuts: potential functional foods for weight control?. Am J Clin Nutr 81 (2005) 7-15
11. 1-3. J Nutr 135 (2005) 2978s-2986s
12. Kim J., Zhang X., Rieger-Christ K.M., Summerhayes I.C., Wazer D.E., Paulson K.E., et al. Suppression of Wnt signaling by the green tea compound (-)-epigallocatechin 3-gallate (EGCG) in invasive breast cancer cells: requirement of the transcriptional repressor HBP1. J Biol Chem 281 (2006) 10865-10875
13. Ahmed S., Wang N., Lalonde M., Goldberg V.M., and Haqqi T.M. Green tea polyphenol epigallocatechin-3-gallate (EGCG) differentially inhibits interleukin-1 β-induced expression of matrix metalloproteinase-1 and -13 in human chondrocytes. J Pharmacol Exp Ther 308 (2004) 767-773
14. Lee Y.K., Bone N.D., Strege A.K., Shanafelt T.D., Jelinek D.F., and Kay N.E. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood 104 (2004) 788-794
15. Hwang J.T., Park I.J., Shin J.I., Lee Y.K., Lee S.K., Baik H.W., et al. Genistein, EGCG, and capsaicin inhibit adipocyte differentiation process via activating AMP-activated protein kinase. Biochem Biophys Res Commun 338 (2005) 694-699
16. Millar A.D., Rampton D.S., Chander C.L., Claxson A.W., Blades S., Coumbe A., et al. Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis. Gut 39 (1996) 407-415
17. Steidler L., Hans W., Schotte L., Neirynck S., Obermeier F., Falk W., et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289 (2000) 1352-1355
18. Myers K.J., Murthy S., Flanigan A., Witchell D.R., Butler M., Murray S., et al. Antisense oligonucleotide blockade of tumor necrosis factor-α in two murine models of colitis. J Pharmacol Exp Ther 304 (2003) 411-424
19. Day A.S., Whitten K.E., and Bohane T.D. Use of complementary and alternative medicines by children and adolescents with inflammatory bowel disease. J Paediatr Child Health 40 (2004) 681-684
20. Langhorst J., Anthonisen I.B., Steder-Neukamm U., Lüdtke R., Spahn G., Michalsen A., et al. Amount of systemic steroid medication is a strong predictor for the use of complementary and alternative medicine in patients with inflammatory bowel disease: results from a German national survey. Inflamm Bowel Dis 11 (2005) 287-295
21. Frei B., and Higdon J.V. Antioxidant activity of tea polyphenols in vivo: evidence from animal studies. J Nutr 133 (2003) 3275S-3284S
22. Katiyar S.K., Challa A., McCormick T.S., Cooper K.D., and Mukhtar H. Prevention of UVB-induced immunosuppression in mice by the green tea polyphenol (-)-epigallocatechin-3-gallate may be associated with alterations in IL-10 and IL-12 production. Carcinogenesis 20 (1999) 2117-2124
23. Yang F., Oz H.S., Barve S., de Villiers W.J., McClain C.J., and Varilek G.W. The green tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factor-κB activation by inhibiting I κB kinase activity in the intestinal epithelial cell line IEC-6. Mol Pharmacol 60 (2001) 528-533
24. Miura Y., Chiba T., Tomita I., Koizumi H., Miura S., Umegaki K., et al. Tea catechins prevent the development of atherosclerosis in apoprotein E-deficient mice. J Nutr 131 (2001) 27-32
25. Porath D., Riegger C., Drewe J., and Schwager J. Epigallocatechin-3-gallate impairs chemokine production in human colon epithelial cell lines. J Pharmacol Exp Ther 315 (2005) 1172-1180
26. Mccafferty D.M. Peroxynitrite and inflammatory bowel disease. Gut 46 (2000) 436-439
27. Seril D.N., Liao J., West A.B., and Yang G.Y. Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. Carcinogenesis 24 (2003) 353-362
28. Barazzone C., and White C.W. Mechanisms of cell injury and death in hyperoxia. Role of cytokines and Bcl-2 family proteins. Am J Respir Cell Mol Biol 22 (2000) 517-519
29. Krieglstein C.F., Cerwinka W.H., Laroux F.S., Salter J.W., Russell J.M., Schuermann G., et al. Regulation of murine intestinal inflammation by reactive metabolites of oxygen and nitrogen: divergent roles of superoxide and nitric oxide. J Exp Med 194 (2001) 1207-1218
30. Peng W., and Kuo S.M. Flavonoid structure affects the inhibition of lipid peroxidation in caco-2 intestinal cells at physiological concentrations. J Nutr 133 (2003) 2184-2187
31. Fuss I.J., Heller F., Boirivant M., Leon F., Yoshida M., Fichtner-Feigl S., et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 113 (2004) 1490-1497
32. Mathew C.G., and Lewis C.M. Genetics of inflammatory bowel disease: progress and prospects. Hum Mol Genet 13 (2004) 161-168
33. Venkatraman A., Ramakrishna B.S., Shaji R.V., Kumar N.S., Pulimood A., and Patra S. Amelioration of dextran sulfate colitis by butyrate: role of heat shock protein 70 and NF-κB. Am J Physiol Gastrointest Liver Physiol 285 (2003) 177-184
34. Ichikawa D., Matsui A., Imai M., Sonoda Y., and Kasahara T. Effect of various catechins on the IL-12p40 production by murine peritoneal macrophages and a macrophage cell line, J774.1. Biol Pharm Bull 27 (2004) 1353-1358